# An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older

> **NCT05765773** · PHASE2 · COMPLETED · sponsor: **Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products** · enrollment: 200 (actual)

## Conditions studied

- Corona Virus Infection
- Vaccine
- COVID-19

## Interventions

- **BIOLOGICAL:** CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI "Chumakov FSC R&D IBP RAS"

## Key facts

- **NCT ID:** NCT05765773
- **Lead sponsor:** Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-01
- **Primary completion:** 2022-10-01
- **Final completion:** 2023-05-19
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05765773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05765773, "An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05765773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*